BIOL vs. RSLS, INBS, VAPO, OSA, SISI, LIPO, GNPX, PCSA, MYMD, and ZVSA
Should you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include ReShape Lifesciences (RSLS), Intelligent Bio Solutions (INBS), Vapotherm (VAPO), ProSomnus (OSA), Shineco (SISI), Lipella Pharmaceuticals (LIPO), Genprex (GNPX), Processa Pharmaceuticals (PCSA), MyMD Pharmaceuticals (MYMD), and ZyVersa Therapeutics (ZVSA). These companies are all part of the "medical" sector.
ReShape Lifesciences (NASDAQ:RSLS) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk.
In the previous week, ReShape Lifesciences had 2 more articles in the media than BIOLASE. MarketBeat recorded 4 mentions for ReShape Lifesciences and 2 mentions for BIOLASE. ReShape Lifesciences' average media sentiment score of 0.00 beat BIOLASE's score of -0.24 indicating that BIOLASE is being referred to more favorably in the news media.
ReShape Lifesciences received 110 more outperform votes than BIOLASE when rated by MarketBeat users. Likewise, 66.22% of users gave ReShape Lifesciences an outperform vote while only 55.60% of users gave BIOLASE an outperform vote.
ReShape Lifesciences has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.
ReShape Lifesciences has higher earnings, but lower revenue than BIOLASE.
BIOLASE has a net margin of -41.97% compared to BIOLASE's net margin of -131.22%. BIOLASE's return on equity of -187.89% beat ReShape Lifesciences' return on equity.
ReShape Lifesciences presently has a consensus target price of $8.00, indicating a potential upside of 4,586.58%. BIOLASE has a consensus target price of $77.00, indicating a potential upside of 51,751.85%. Given ReShape Lifesciences' higher probable upside, analysts clearly believe BIOLASE is more favorable than ReShape Lifesciences.
22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 0.1% of ReShape Lifesciences shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
ReShape Lifesciences and BIOLASE tied by winning 7 of the 14 factors compared between the two stocks.
Get BIOLASE News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
